Genfit adds $20M as Ipsen records strong sales for liver drug
Source: SeekingAlpha
2026-02-12 13:52:01 ET
More on Genfit, Ipsen S.A.
- Ipsen S.A. (IPSEY) Q4 2025 Earnings Call Transcript
- Ipsen S.A. 2025 Q4 - Results - Earnings Call Presentation
- Ipsen S.A. (IPSEY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Ipsen S.A. Non-GAAP EPS of €12.09, revenue of €3.68B; sets full-year 2026 guidance and mid-term outlook
- Ipsen rises on FDA breakthrough therapy status for blood cancer therapy
Read the full article on Seeking Alpha
For further details see:
Genfit adds $20M as Ipsen records strong sales for liver drug
Genfit
NASDAQ: GNFTF
GNFTF Trading
-16.98% G/L:
$7.87 Last:
1,000 Volume:
$9.48 Open:
GNFTF Latest News
March 09, 2026 01:00:00 pm
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
February 26, 2026 12:00:00 pm
GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update
GNFTF Stock Data
$361,801,977
47,868,958
N/A
30
N/A
Biotechnology & Life Sciences
Healthcare
FR
Loos
